Keyword: CMS

The Senate voted in favor of drug pricing in DTC ads, while HHS works on a transparency proposal for Medicare and Medicaid.

Federal officials unveiled changes to Medicare Part B this week that could result in lower sales for Amgen and Regeneron.

CMS has pulled the plug on a plan to implement indication-specific pricing on Novartis' CAR-T drug Kymriah.

As federal drug pricing moves have floundered, state officials got busy. But Massachusetts is discovering there's a limit to drug-pricing innovation.

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's requested add-on payment.

Amid a particularly severe flu season, FDA chief Scott Gottlieb said the "holy grail" of vaccines—a shot that fights any strain of virus—is years off.

Sick of dealing with generic drug shortages and price increases, five large U.S. health systems are forming their own drugmaker.

Payers are now holding up Spark's $850,000 gene therapy as an example of how innovative drug developers can help payers afford pricey new treatments.

Some critics point to the $373,000 price for Gilead's Yescarta as the problem holding up reimbursement, but it may be more nuanced than that.

A new report found that spending on pharmaceuticals grew at a much slower rate last year than in recent history.